


# IMMA health

Unlock the Fertility Market



# Assisted Reproduction Technologies (ART) are costly, inefficient, stressful & burdensome



Half of patients **abandon** this path to parenthood

**Cost to Baby**

Av. cost US \$60K

**Low Success**

Av. rate <30%

**Life Disturbance**

~12 visits/cycle

**Time to Baby**

1-2 year

**Drop Out Rate**

50% drop out at 1st consultation

# Transvaginal Scans (TVS) is a key Pain Point

\*90% doctors use ultrasound exams at each critical decision point during an IVF cycle, and yet only 3 to 4 TVS are performed on average during ovarian stimulation



## Major Life Disturbance for Patients

- **Physical presence** required at the clinic
- **Time Loss** and Loss of Productivity
- **Stress** and Anxiety
- **Lack of Access**

## Capacity Limitation for Clinics


- **Ultrasound Room** Capacity Limited
- **Sonographer & REI** Schedules Limited
- **Workflow Bottleneck** for clinics

## Sub-optimal Monitoring & Egg Quality

- **Up to 12 scans** required\* for ideal monitoring
- **Variability** Inter and intra operator
- **Low oocyte cohort quality**

# IMMA At Home Transvaginal Self-Scanning Solution

**Easy Transvaginal  
Ultrasound Self-Scan**  
In Women's Hands



**AI/ML-powered Ovarian  
Follicular Monitoring Tool**  
In Physician's Hands

# IMMA benefits Patients & Clinics



**At Home Self Scan**



**UNLIMITED  
COMPARABLE SCANS**



**Ovarian Follicular  
Monitoring Tool**



## Improved Patient Experience

- Reduced # of clinic visits
- Time Saving
- Comfort of at-home self-scans
- Reduced stress and anxiety

## Increased # Patients for Clinics

- Remote care
- Greater access
- Enhanced patient engagement



## Expanded Clinics Capacity

- Improved resource utilization
- no sonographer, no scanning room
- Workflow optimization

## Improved Oocyte Quality

- Individual follicle monitoring
- Personalized hormonal Tx
- Improved physician decision (Trigger & Pick up timing)
- New Oocyte quality biomarkers

# An Underserved Market ready to thrive with IMMA



## \*ART Growth Drivers :

1. Decrease in fertility rates
2. IVF policy coverage and employee benefits increase
3. IVF sector consolidation, PE capital entering, 50% IVF Clinics held by 8 big IVF chains
4. Rise of egg freezing (+40% during COVID)

## Interview

Shanna Swan: 'Most couples may have to use assisted reproduction by 2045'

Zoë Corbyn



## Need for Remote Ultrasound Solution :

1. Rise of remote IVF clinics model
2. Shortage of sonographers & fertility specialists
3. Rural healthcare shortage

# IMMA Technology Value Proposition



**ULTRASOUND SIGNAL ACQUISITION**  
HW & SW


**IMAGE ANALYSIS**  
SW on premises & Cloud, GPU

**DECISION SUPPORT**  
SW on Cloud, GPU, SW


IMMA Box



BACK-END SYSTEM



MONITORING TOOL



CORE TECHNOLOGIES

MECHATRONIC SYSTEM

PROBE ADAPTATION

ACQUISITION SIGNAL SW

EMBEDDED SW

IMAGE PROCESSING & AI

DATA SIMULATOR

ML & AI ALGORITHM

CLOUD SW

CYBER SECURITY

Automated 360° self scanning acquisition/Standardized unfiltered data

Automated structures recognition  
Volumetric 3D imaging  
reconstitution

Individual follicular monitoring  
Predictive insight  
Personalized medicine


# IMMA a unique At-home Remote Monitoring Solution



	GE noAVCGE	echopen	clarius	Pulsenmore	vortex IMAGING	IMMA	MIMFERTILITY.
<b>Hardware</b>							
Transvaginal	✓	✗	✓	✓	✗	✓	✗
Ultraportable	✗	✓	✓	✓	✓	✓	✗
Self scan No HCP support	✗	✗	✗	✗	✗	✓	✗
Removes operator biases	✗	✗	✗	✗	✗	✓	✗
2D & 3D	✓	✗	✗	✗	✓	✓	✓
Calculations Run on cloud	✗	✗	✗	✗	✓	✓	✓
Individual Ovarian follicular Monitoring	✗	✗	✗	✗	✗	✓	✗
						<b>HW+SW</b>	

**Software**

# IMMA Business Model aligns Stakeholder Interests



## NO CHANGE in the FLOW of MONEY

- IMMA charges Clinics
- Clinics charges Patients



### CLINICS

- Increased Revenue through additional patients
- Decrease Cost per Cycle through HR and Asset optimization

**☑ Increased Gross Margin**


# IMMA today Achievements



## IMMA Inception

Jan. 2021

Today



# Top Class Team

Supported by experts to make it happen



Beatrice Chemla, CEO



Nadia Prisant, MD, CSO



Herve Stealth, VP R&D, COO



Daphné Seroussi, CFO

## MEDICAL



Hananel Holzer



Martine Valière



Pietro Bortoletto



John Petrozza



Charles Tibi



## SCIENTIFIC



Mickael Tanter



Jacob (Kobi) Glazer



Gila Tolub



# Use of Proceed and Timeline

IMMA is currently raising its **seed round of \$5M** to complete MVP development and obtain its MVP-FDA approval in the next 16 months

